Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Works matching IS 01676997 AND DT 2015 AND VI 33 AND IP 6
Results: 17
1
2
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1197, doi. 10.1007/s10637-015-0281-z
- By:
- Publication type:
- Article
3
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1242, doi. 10.1007/s10637-015-0285-8
- By:
- Publication type:
- Article
4
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1206, doi. 10.1007/s10637-015-0286-7
- By:
- Publication type:
- Article
5
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1217, doi. 10.1007/s10637-015-0288-5
- By:
- Publication type:
- Article
6
Blinatumomab for the treatment of acute lymphoblastic leukemia.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1271, doi. 10.1007/s10637-015-0289-4
- By:
- Publication type:
- Article
7
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1280, doi. 10.1007/s10637-015-0290-y
- By:
- Publication type:
- Article
8
Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1151, doi. 10.1007/s10637-015-0291-x
- By:
- Publication type:
- Article
9
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1267, doi. 10.1007/s10637-015-0297-4
- By:
- Publication type:
- Article
10
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1248, doi. 10.1007/s10637-015-0293-8
- By:
- Publication type:
- Article
11
Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1162, doi. 10.1007/s10637-015-0294-7
- By:
- Publication type:
- Article
12
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1263, doi. 10.1007/s10637-015-0295-6
- By:
- Publication type:
- Article
13
Identification of a novel compound (β-sesquiphellandrene) from turmeric ( Curcuma longa) with anticancer potential: comparison with curcumin.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1175, doi. 10.1007/s10637-015-0296-5
- By:
- Publication type:
- Article
14
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1257, doi. 10.1007/s10637-015-0292-9
- By:
- Publication type:
- Article
15
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1225, doi. 10.1007/s10637-015-0298-3
- By:
- Publication type:
- Article
16
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1232, doi. 10.1007/s10637-015-0299-2
- By:
- Publication type:
- Article
17
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1187, doi. 10.1007/s10637-015-0278-7
- By:
- Publication type:
- Article